0001104659-15-049022.txt : 20150630
0001104659-15-049022.hdr.sgml : 20150630
20150630184733
ACCESSION NUMBER: 0001104659-15-049022
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150630
FILED AS OF DATE: 20150630
DATE AS OF CHANGE: 20150630
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CATABASIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001454789
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 1400E, SUITE B14202
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-349-1971
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 1400E, SUITE B14202
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GALAKATOS NICHOLAS
CENTRAL INDEX KEY: 0001252522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37467
FILM NUMBER: 15962730
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
a4.xml
4
X0306
4
2015-06-30
0
0001454789
CATABASIS PHARMACEUTICALS INC
CATB
0001252522
GALAKATOS NICHOLAS
C/O CLARUS VENTURES, LLC
101 MAIN STREET SUITE 1210
CAMBRIDGE
MA
02142
1
0
1
0
Common Stock
2015-06-30
4
C
0
1618676
A
1618676
I
See Footnotes
Common Stock
2015-06-30
4
C
0
757117
A
2375793
I
See Footnotes
Common Stock
2015-06-30
4
P
0
376695
12
A
2752488
I
See Footnotes
Series A Preferred Stock
2015-06-30
4
C
0
20800000
0
D
Common Stock
1618676
0
I
See Footnotes
Series B Preferred Stock
2015-06-30
4
C
0
9728971
0
D
Common Stock
757117
0
I
See Footnotes
Stock Option (right to buy)
12.21
2015-06-30
4
A
0
11094
0
A
2025-06-29
Common Stock
11094
11094
D
The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus.
The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Dr. Galakatos, Denis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Galakatos disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
This option was granted on June 30, 2015 and vests over three years, with one-third of the shares vesting on each anniversary of the grant date until the third anniversary of the grant date.
/s/ Nicholas Galakatos
2015-06-30